Targeting the orthosteric binding pocket and the unique ECL2 configuration may allow for the design of selective agonists or antagonists that can either enhance or inhibit GPR17’s function, offering novel therapeutic approaches for MS and other neurodegenerative diseases. The gene discussed is GPR17; the disease is myeloid sarcoma.